5Levi F, Misset J L, P, rienza S, et ai. A chronopharmaco-logic phase [I clinical trial with 5-fluorouracil, folinieacid,and oxaliplatin using an ambulatory multichannelprogrammable pure. High antitumor effctiveness a-gainst metastatic eolorectal cancer EJJ. Cancer, 1992,69:893.
6Adelsberger H, Quasthoff S,Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons[J]. Eur J Pharmacol, 2000,406 (1) : 25.
3De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.Eur J Cancer Clin Oncol, 1988, 24:1499-1503.
4Ajani JA. Current status of therapy for advanced gastric carcinoma.Oncology, 1998, 12:99-102.
5Raymond E, Charley SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9:1053-1071.
6De Gramont A, Figer A, Seymonr M, et al. Leucovorin and fluorouracil with or without oxaliplatin as frist-line treatment in advanced colorectal cancer. J Clin Oncol, 2000,18:2938-2947.
7De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol,1997, 15:808-815.
9Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
10Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
